All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

abametapir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5403	1762-34-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: abametapir xeglyze Ha44	Abametapir is a metalloproteinase inhibitor. Metalloproteinases have a role in physiological processes critical to egg development and survival of lice. Molecular weight: 184.24 Formula: C12H12N2 CLOGP: 2.56 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 25.78 ALOGS: -2.27 ROTB: 1 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
July 24, 2020	FDA	DR REDDYS LABS SA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	P03AX07	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES Other ectoparasiticides, incl. scabicides

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pediculosis capitis	indication	81000006	DOID:5501

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.74%	XEGLYZE	HATCHTECH	N206966	July 24, 2020	DISCN	LOTION	TOPICAL	8212038	July 16, 2024	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
0.74%	XEGLYZE	HATCHTECH	N206966	July 24, 2020	DISCN	LOTION	TOPICAL	9839631	July 16, 2024	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
0.74%	XEGLYZE	HATCHTECH	N206966	July 24, 2020	DISCN	LOTION	TOPICAL	7812163	Oct. 28, 2026	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
0.74%	XEGLYZE	HATCHTECH	N206966	July 24, 2020	DISCN	LOTION	TOPICAL	10292389	Dec. 17, 2034	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
0.74%	XEGLYZE	HATCHTECH	N206966	July 24, 2020	DISCN	LOTION	TOPICAL	July 24, 2025	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
C-C chemokine receptor type 5	GPCR	P51681	CCR5_HUMAN		EC50	5.64		CHEMBL
C-C chemokine receptor type 1	GPCR	P32246	CCR1_HUMAN		EC50	4.80		CHEMBL
C-C chemokine receptor type 8	GPCR	P51685	CCR8_HUMAN		EC50	5.12		CHEMBL

External reference:

ID	Source
D10687	KEGG_DRUG
6UO390AMFB	UNII
C4519258	UMLSCUI
EI3	PDB_CHEM_ID
CHEMBL2205807	ChEMBL_ID
15664	PUBCHEM_CID
DB11932	DRUGBANK_ID
018457	NDDF
926368006	SNOMEDCT_US
926389002	SNOMEDCT_US
2475532	RXNORM
38681	MMSL
9829	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Xeglyze	HUMAN PRESCRIPTION DRUG LABEL	1	43598-921	LOTION	0.74 g	TOPICAL	NDA	25 sections